Heterocyclic compounds, compositions, methods of preparation and uses thereof
AssigneeOrganon R&D Finland Ltd.
InventorsTero Linnanen, Leena Hirvelä, Kaisa Illikainen, Marjo Hakola, Sanna Niinivehmas, Olli Pentikäinen, Camilla Stjernschantz
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) to salts, solvates and solvates of salts thereof, and to pharmaceutical compositions comprising these compounds as active ingredients. The invention further relates to their use as aldo-keto reductase family 1 C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5, HSD17B5) and prostaglandin (PG) F2α synthase, inhibitors. The invention further relates to methods for their preparation, and to uses of said compounds.
Claims20
A compound of formula (I)
- wherein
- R1 is a group selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-perhaloalkyl, (CH2)mOR′, (CH2)mN(R′)2, 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R11;
- R2 is a group selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-perhaloalkyl, (CH2)mOR′, (CH2)mN(R′)2, 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R12;
- or
- R1 and R2, together with the ring nitrogen atom they are attached to, form a 4- to 11-membered unsaturated or aromatic heterocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle, and said heterocycle being optionally substituted with one to six substituent(s) each independently selected from R13;
- R3 is a group selected from 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R31;
- R11 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′COR″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
- R12 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, NHCOR″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
- R13 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′C(O)R″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
- R31 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′C(O)R″, C(═NH)R″, C(═N—OR′H)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
- each R′ is independently selected from H, C1-6-alkyl, C1-6-haloalkyl, and C1-6-perhaloalkyl, or when part of any N(R′)2 both R's, together with the nitrogen they are attached to, may form a 3- to 6-membered aliphatic or aromatic heterocyclic ring comprising 1 to 4 heteroatoms each independently selected from N, S, and O;
- each R″ is independently selected from C1-6-alkyl, C1-6-haloalkyl, and C1-6-perhaloalkyl;
- X is O or S;
- m is 0-6;
- and
- n is 1-6;
- or
- a salt, solvate or solvate of a salt thereof.
A compound, selected from the group consisting of:
- 2-(4-fluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (4);
- 2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (12);
- 2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine-5-carbonyl)piperidin-4-ylidene)acetonitrile (13);
- 2-(4-chlorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (18);
- 2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (25);
- 2-(3,4-difluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (41);
- 2-(2,4-difluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (42);
- 2-(3,4-difluorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (43);
- 2-(3,4-difluorophenyl)-2-(1-(5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-7-carbonyl)piperidin-4-ylidene)acetonitrile (44);
- 2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)-2-(1H-indazol-4-yl)acetonitrile (48);
- 2-(5-chloropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (67);
- 2-(4-chlorophenyl)-2-(1-(4-(hydroxymethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (74);
- 2-(3-chlorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (80);
- 2-(5-fluoropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (84);
- 1-(4-((3-chlorophenyl)(cyano)methylene)piperidine-1-carbonyl)piperidine-4-sulfonamide (99);
- 2-(4-chlorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (113);
- 2-(1-(4-(hydroxymethyl)piperidine-1-carbonyl)piperidin-4-ylidene)-2-(1-methyl-1H-indazol-7-yl)acetonitrile (118);
- 2-(1H-indazol-4-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (138);
- 2-(3-chlorophenyl)-2-(1-(4-(2-hydroxyethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (140);
- 2-(4-chlorophenyl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (141);
- 2-(1H-indazol-4-yl)-2-(1-(4-methoxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (144);
- 2-(1H-indazol-4-yl)-2-(1-(4-(trifluoromethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (145);
- 2-(1-(3-oxa-8-azabicyclo[3.2.1]octane-8-carbonyl)piperidin-4-ylidene)-2-(3-chlorophenyl)acetonitrile (156);
- 2-(5-chloropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (161);
- or
- a salt, solvate or solvate of a salt thereof.
Dependencies are inferred from the claim text.